Transcend Medical Launches the Transcend Vold Gonio Lens (TVG) for Improved Visualization During Micro-Invasive Glaucoma Surgery
TVG Allows Physicians to Gently Stabilize Eye Movement and to Reduce Scope Tilt During Micro-Invasive Glaucoma Surgery
CHICAGO, IL--(Marketwire - Nov 12, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, today announced the commercial availability of the Transcend Vold Gonio Lens (TVG). The new lens is specifically designed to improve visualization and surgical control of the eye during micro-invasive glaucoma surgery (MIGS) procedures, a growing class of less-invasive surgical glaucoma treatments.
"The TVG is designed to allow the surgeon to fine-tune visualization with minimal rotation of the microscope, giving an enhanced view of the angle of the eye, which is very beneficial for a variety of ab interno glaucoma procedures," said Quang H Nguyen, MD at Scripps Clinic Torrey Pines in San Diego. "It also enables better globe control without distorting the anterior chamber, which can sometimes happen with conventional gonio lenses."
Designed in collaboration with Steven Vold, MD, the TVG consists of a floating, 1.2X magnification lens and a stabilization ring. The stabilization ring improves control of the eye, while the floating lens minimizes pressure on the cornea and enhances the view of the iridocorneal angle -- essential for MIGS procedures.
"Advancements in visualization technologies will be an important component in the success of the new generation of 'micro-invasive' glaucoma procedures," said Brian Walsh, President and Chief Executive Officer of Transcend Medical. "The TVG represents the next generation of surgical gonioscopy technology."
About Transcend Medical, Inc.
Transcend Medical (www.transcendmedical.com) is focused on the development of medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. It is estimated that over 4 million people in the U.S. and roughly 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly 6 million in the U.S. and over 70 million worldwide by the year 2015.
Transcend Medical is also developing the CyPass Micro-Stent®, currently under clinical investigation in the United States for the treatment of mild-to-moderate glaucoma in combination with cataract surgery.
